EffRx Pharmaceuticals SA is an innovative company that exploits drug delivery technologies to improve the efficacy and tolerability of existing approved compounds with a focus on drugs, with high commercial potential. Once developed, we partner these products with established pharmaceutical companies. Our goal is to become a global provider of products, based on alternative drug delivery technologies for both the prescription and OTC markets, by applying our technologies to well established proven compounds and developing reformulated products with reduced gastrointestinal side effects, better absorption and faster onset of action.
Thereby generating better products for patients in a cost effective manner. The lead product, Steovess® (70mg Alendronate) for the treatment of osteoporosis has been accepted for national approvals in the European Union (DCP) in December 2011. Approval for the same drug in the US under the brand name Bionosto® has been granted by the FDA in March 2012. Bionosto® is being sold in the US by Mission Pharmacal since October 1st 2012. EffRx is actively seeking partnerships for the distribution of Binosto®/Steovess® in other regions of the world.